Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma ; volume:482 ; number:6 ; day:17 ; month:4 ; year:2023 ; pages:975-982 ; date:6.2023
Virchows Archiv ; 482, Heft 6 (17.4.2023), 975-982, 6.2023
- Urheber
-
Davidson, Ben
Doutel, Delfim
Holth, Arild
Nymoen, Dag Andre
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00428-023-03541-6
- URN
-
urn:nbn:de:101:1-2023091615283494467329
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 09:00 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Davidson, Ben
- Doutel, Delfim
- Holth, Arild
- Nymoen, Dag Andre
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
Role of integrins in the metastatic spread of high-grade serous ovarian cancer
Role of integrins in the metastatic spread of high-grade serous ovarian cancer
KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
High-grade serous ovarian cancer: the clone wars
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
The metastatic capacity of high-grade serous ovarian cancer cells changes along disease progression: inhibition by mifepristone
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Correction to: Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
Role of integrins in the metastatic spread of high-grade serous ovarian cancer
Role of integrins in the metastatic spread of high-grade serous ovarian cancer
KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
High-grade serous ovarian cancer: the clone wars
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
The metastatic capacity of high-grade serous ovarian cancer cells changes along disease progression: inhibition by mifepristone
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Correction to: Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
Role of integrins in the metastatic spread of high-grade serous ovarian cancer
Role of integrins in the metastatic spread of high-grade serous ovarian cancer
KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
High-grade serous ovarian cancer: the clone wars
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
The metastatic capacity of high-grade serous ovarian cancer cells changes along disease progression: inhibition by mifepristone
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
First-Line Management of Advanced High-Grade Serous Ovarian Cancer